---
title: "Biomea Fusion | 10-Q: FY2025 Q1 EPS Misses Estimate at USD -0.8"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/238788078.md"
datetime: "2025-05-05T20:12:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/238788078.md)
  - [en](https://longbridge.com/en/news/238788078.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/238788078.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/238788078.md) | [English](https://longbridge.com/en/news/238788078.md)


# Biomea Fusion | 10-Q: FY2025 Q1 EPS Misses Estimate at USD -0.8

EPS: As of FY2025 Q1, the actual value is USD -0.8, missing the estimate of USD -0.6011.

### Segment Revenue

Biomea Fusion, Inc. has not generated any revenue from product sales since its inception.

### Operational Metrics

-   **Net Loss**: The company reported a net loss of - $29.3 million for the three months ended March 31, 2025, compared to a net loss of - $39.1 million for the same period in 2024.
-   **Operating Expenses**: Total operating expenses decreased from $41.1 million in Q1 2024 to $29.7 million in Q1 2025.
-   **Research and Development Expenses**: R&D expenses decreased by $10.9 million, primarily due to reduced clinical activities and manufacturing costs.
-   **General and Administrative Expenses**: G&A expenses decreased by $0.5 million, mainly due to reduced personnel-related expenses.

### Cash Flow

-   **Net Cash Used in Operating Activities**: The company used - $25.7 million in operating activities during the three months ended March 31, 2025, compared to - $32.0 million in the same period in 2024.
-   **Net Cash Used in Investing Activities**: No cash was used in investing activities during the three months ended March 31, 2025.
-   **Net Cash Provided by Financing Activities**: Financing activities provided $3.3 million during the three months ended March 31, 2025, primarily from the issuance of common stock under the 2022 ATM Program.

### Unique Metrics

-   **Stock-Based Compensation Expense**: Total stock-based compensation expense was $3.2 million for the three months ended March 31, 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to focus on developing icovamenib for metabolic disorders, specifically type 1 and type 2 diabetes, and aims to conclude oncology studies while exploring partnerships for its oncology assets.
-   **Non-Core Business**: Biomea Fusion, Inc. intends to explore partnerships to advance its oncology assets, including BMF-500, while concentrating internal resources on metabolic disorders.
-   **Priority**: The company acknowledges the need for additional capital to fund operations and plans to raise funds through public or private equity offerings, debt financings, collaborations, and licensing arrangements.

### 相關股票

- [Biomea Fusion (BMEA.US)](https://longbridge.com/zh-HK/quote/BMEA.US.md)

## 相關資訊與研究

- [05:00 ETRealta Fusion and Commonwealth Fusion Systems Form Strategic Partnership to Commercialize Magnetic Mirror Fusion Energy](https://longbridge.com/zh-HK/news/281494035.md)
- [How fusion power works and the startups pursuing it](https://longbridge.com/zh-HK/news/280024447.md)
- [Top Executive Makes Bold Move with Major Stock Purchase in Biomea Fusion](https://longbridge.com/zh-HK/news/269803544.md)
- [Oppenheimer Sticks to Their Buy Rating for Biomea Fusion (BMEA)](https://longbridge.com/zh-HK/news/264342800.md)
- [Interim CEO Makes Bold Move with Major Stock Purchase](https://longbridge.com/zh-HK/news/268694166.md)